Compare ACFN & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | NEPH |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 40.1M |
| IPO Year | N/A | 2004 |
| Metric | ACFN | NEPH |
|---|---|---|
| Price | $17.06 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 7.4K | ★ 33.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ $6.63 | $380.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $12.42 | $2.66 |
| 52 Week High | $33.00 | $6.42 |
| Indicator | ACFN | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 56.08 |
| Support Level | $15.95 | $3.64 |
| Resistance Level | $17.20 | $3.78 |
| Average True Range (ATR) | 0.76 | 0.21 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 26.13 | 76.39 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.